Viking Therapeutics Showcases Momentum Amid Mixed Investor Sentiment and Phase 3 Trials
PILLAR DIAGNOSTIC // WEEK 15
“Early signs of Phase 3 progress are colliding with underwhelming investor sentiment; absent any binding external barrier, this gap should close as sentiment-driven buying returns once momentum builds.”
Proposed action
Accumulate on dips for a tactical long, awaiting a clear breakout signal; avoid chasing strength in isolation.
THE MECHANICS
Tape & flow
No clear tape flow or positioning shifts, and no discernible forced buying or selling pressure.
THE MACHINE
Operational momentum
VK2735 is in late-stage subcutaneous Phase 3 trials (VANQUISH-1 and VANQUISH-2) with the oral formulation slated for Phase III in 3Q 2026, and the NASH fibrosis candidate achieved both primary and secondary endpoints in a Phase 2b study.
THE MAP
Structure & constraints
—
THE MOOD
Consensus & positioning
Investors are optimistic about Viking’s next-gen GLP-1/glucagon therapies, anticipating breakthrough potential, significant upside, and undervaluation, while also weighing cautions around phase 3 timing, forthcoming earnings declines, and mixed valuation anchors ranging from deeply undervalued to premium multiples.